Tris Pharma has set its sights on an FDA filing for pipeline drug cebranopadol before the end of this year after the drug achieved significant pain relief in abdominoplasty patients in a late-stage ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results